Filana Therapeutics Announces Publication in Epilepsia of Preclinical Simufilam DataAUSTIN, Texas, April 15, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company focused on developing therapies for Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced publication in Epilepsia of preclinical data showing that simufilam attenuated seizure progression in a well-accepted mouse model of severe TSC-related epilepsy1. The results support the continued evaluation of simufilam for the treatment of TSC-related epilepsy, which affects approximately 45,000 people in the U.S.2,3. Simufilam is an oral small molecule intended to modulate filamin A protein.
Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial ResultsWorking to advance TSC-related epilepsy program, with a focus on capital efficiency
Cassava Sciences Announces Name Change to Filana Therapeutics, Inc.New corporate identity reflects the Company’s mission to develop novel medicines to modulate filamin A and address unmet needs in treating TSC-related epilepsy
